Young Kwang Chae: Nivolumab/Ipilimumab can be effective in select non-epithelial ovarian cancer
Young Kwang Chae, Associate Professor of Medicine, medical oncologist, and physician-scientist at Northwestern University’s Feinberg School of Medicine, shared on X:
“Go SWOG DART team! Our new publication in CCR! Nivolumab/Ipilimumab can be effective in select non-epithelial ovarian cancer (granulosa cell tumor, ORR 25%, 1CR&1PR/8, lasting >4 years).”
SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer
Authors: Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Kelly J. Wilkinson, Emily M. Whitman-Purves, Jayanthi Lea, John M. Schallenkamp, Nabil Adra, Leonard J. Appleman, Mitchell Alden, Jessica Thomes Pepin, John A. Ellerton, Andrew Poklepovic, Adam Walter, Murtuza M. Rampurwala, William R. Robinson, Hye Sung Kim, Liam IL-Young Chung, Christine M. McLeod, Gabby Lopez, Helen X. Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock
Young Kwang Chae is an Associate Professor of Medicine, medical oncologist, and physician-scientist at Northwestern University’s Feinberg School of Medicine. His work focuses on personalized cancer therapy and precision medicine, with expertise in early-phase clinical trials, first-in-human studies, novel combination therapies, targeted therapy, and immunotherapy.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023